JUL 30, 2020 2:21 PM PDT

Cats Successfully Treated with Gene Therapy

WRITTEN BY: Annie Lennon

While gene therapy is a promising treatment for multiple diseases caused by a genetic mutation, getting gene therapy agents beyond the brain-blood barrier- the brain's protective layer- is a challenge. Now, researchers from the University of Pennsylvania may have found a solution. 

Gene therapy works by delivering a functional version of a gene inside a virus- known as a viral vector- to a mutated version. In doing so, the functional version overrides the mutated version's effects and theoretically corrects the condition. While steady progress has been made in correcting neurogenetic diseases in rodents, applying the same treatments in larger mammals has only partially worked. 

In this new study, the researchers used cats to assess the efficacy of gene therapy to treat alpha-mannosidosis. The condition occurs naturally in cats from a mutated copy of the alpha-mannosidase gene. To assess whether their new gene therapy would work, they injected it into the cats' carotid artery for direct delivery to the brain. Cats either received a high or low dose of the vector. 

In the end, the researchers found that treated cats had a significantly delayed onset of certain neurological symptoms and a longer lifespan. They also noted that those on higher doses tended to live the longest. 

"It's a big advance," says John Wolfe, lead author of the study. "Nobody has been able to treat the whole brain of a large-brained animal before. We're hopeful that this will translate into clinical use in humans."

Although promising results, Wolfe cautions that the treatment did not cure the cats of their condition- although it did improve their symptoms. He added that they do not know whether the therapy impacted their mental ability. Thus, before any conclusions can be made about the treatment, further research is needed from more animal studies. 

 

Sources: Medical XpressOxford Academic

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
SEP 23, 2021
Drug Discovery & Development
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
SEP 23, 2021
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
Last week, the United States Food and Drug Administration (FDA) granted approval for the first oral therapy to ...
OCT 19, 2021
Microbiology
An Antibiotic May be Able to Reduce Inflammatory Pain
OCT 19, 2021
An Antibiotic May be Able to Reduce Inflammatory Pain
The gastrointestinal tract is full of microbes, all with their own genomes and characteristics. Some of those microbes a ...
OCT 28, 2021
Technology
New Electroceutical Device Targets Splenic Nerves For Therapeutic Benefit
OCT 28, 2021
New Electroceutical Device Targets Splenic Nerves For Therapeutic Benefit
Electroceuticals—the use of electricity to change certain biological functions with the goal of treating diseases& ...
OCT 29, 2021
Drug Discovery & Development
Common Antidepressant Reduces COVID-19 Hospitalizations by 30%
OCT 29, 2021
Common Antidepressant Reduces COVID-19 Hospitalizations by 30%
The widely-available antidepressant fluvoxamine reduces COVID-19 hospitalizations by 30%. The corresponding study was pu ...
NOV 22, 2021
Microbiology
Researchers Solve the Structure of the HIV Capsid, May Be a New Drug Target
NOV 22, 2021
Researchers Solve the Structure of the HIV Capsid, May Be a New Drug Target
Though treatments are available, there is no cure or vaccine from HIV, which impacts about 38 million people worldwide. ...
NOV 30, 2021
Immunology
Sweet Escape: A Sugar Molecule Helps HIV Remain Incognito
NOV 30, 2021
Sweet Escape: A Sugar Molecule Helps HIV Remain Incognito
HIV is a master of disguise. Once the virus enters the body, it has a number of sophisticated mechanisms through which i ...
Loading Comments...